NEW YORK (GenomeWeb News) — Shares in Gene Logic were down 15.47 percent, or $.30, at $1.64 in midday trading after the company this morning said third-quarter revenue slid 39 percent, and that it plans to sell its preclinical services division.
 
After stating in September that the preclinical services segment would not be put on the block, today Gene Logic said it has hired an investment firm to help it divest the unit, and is currently in discussions for the sale.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.